LXRXClinical Trials•globenewswire•
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings
Sentiment:Positive (70)
Summary
(NASDAQ:LXRX) Presentations collectively highlight pilavapadin’s potential to improve pain management care for patients with diabetic peripheral neuropathic pain (DPNP)
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 11, 2025 by globenewswire